SPAQ

S Kant Healthcare

Legend
Product category

  • Sulfadoxine-pyrimethamine + amodiaquine in child-friendly dispersible formulation

  • Chemoprevention
Therapeutic indication
  • Seasonal Malaria Chemoprevention for children 3 to 59 months in eligible region
Dosing

  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months 
Efficacy

  • 75% reduction in malaria episodes in pivotal trials
Key features

  • Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission

  • Average cost to protect a child: US$3.40 per year (drug costs + delivery)
Status

  • Dossier submitted for Prequalification and ERP approval
Next milestone
  • First distributions in countries expected in 2019
MMV Project Director

  • Dr André-Marie Tchouatieu